Arcutis Biotherapeutics, Inc.
ARQT Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$31.20
KIRA · Stoqly’s AI analyst, in plain words
- Arcutis Biotherapeutics, Inc. had $376M of revenue in fiscal 2025, up 91.3% on the year before.
- Its operating margin was −3.3%, up 62.1 pts: of every 100 in sales, about −3 is left after running the business.
- Arcutis Biotherapeutics, Inc. lost $16.1M in fiscal 2025.
- Free cash flow was −$6.3M in fiscal 2025, −1.7% of revenue.
- Arcutis Biotherapeutics, Inc. has $112M more cash than debt.
Market cap
$4.2B
P/E
141.8x
Revenue
$376M
Net income
−$16.1M
Free cash flow
−$6.3M
Operating margin
−3.3%
Arcutis Biotherapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+91.3%
Yes. Sales grew 91.3% last year.
Does it make a profit?
−4.3%
No. It lost money last year.
Does profit turn into cash?
−1.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
How is the share priced?
141.8x
One share costs 141.8 times its yearly profit per share.
What Arcutis Biotherapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 25, 2026
- Legal name
- Arcutis Biotherapeutics, Inc.
- CIK
- 0001787306
Arcutis Biotherapeutics, Inc. · ARQT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $3.7M | $59.6M | $197M | $376M |
| Revenue growth | — | — | 1,517.1% | 229.7% | 91.3% |
| Gross margin | — | 79.5% | 91.6% | 90.3% | 90.2% |
| Operating margin | — | −8,183.0% | −404.5% | −65.3% | −3.3% |
| Net income | −$206M | −$311M | −$262M | −$140M | −$16.1M |
| Net margin | — | −8,449.8% | −439.8% | −71.3% | −4.3% |
| Diluted EPS | −$4.18 | −$5.66 | −$3.78 | −$1.16 | −$0.13 |
| Cash | |||||
| Cash from operations | −$175M | −$258M | −$247M | −$112M | −$5.6M |
| Capital expenditure | $1.0M | $0.3M | $0.4M | $0.1M | $0.7M |
| Free cash flow | −$176M | −$258M | −$247M | −$112M | −$6.3M |
| FCF margin | — | −7,000.8% | −415.2% | −57.1% | −1.7% |
| Share count change | 38.5% | 11.4% | 25.9% | 74.5% | 5.2% |
| Debt and strength | |||||
| Cash and short-term investments | $387M | $410M | $272M | $228M | $221M |
| Debt incl. finance leases | $72.4M | $198M | $202M | $107M | $109M |
| Shareholders' equity | $298M | $210M | $88.7M | $158M | $189M |
| Current ratio | 12.1x | 11.6x | 7.1x | 4.1x | 3.2x |
| Interest coverage | — | −19.3x | −8.1x | −4.7x | −1.0x |
| Returns and quality | |||||
| Return on capital | — | — | −1,023.6% | −275.7% | −12.5% |
| Return on equity | −72.6% | −122.8% | −175.8% | −113.8% | −9.3% |
| Return on tangible equity | −69.3% | −153.9% | −318.8% | −94.6% | −9.2% |
| Piotroski F-score | 1 | 2 | 3 | 4 | 4 |
| Altman Z'' | 2.1 | −3.0 | −8.3 | −7.3 | −3.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$16.3M
11 insiders
Of sales under plans
79%
$12.9M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Arcutis Biotherapeutics, Inc. · ARQT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $31.20 a share, the company is worth $4.2B: 141.8 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001787306). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.